Plasma levels of TNFα also increased in CLL patients treated with ruxolitinib for 4 (C2) or 8 (C3) weeks (Figure 1D) while IL-10 levels decreased (Figure 1E). Here, TNF is linked to B-cell chronic lymphocytic leukemia.